ZYXI Investors Have the Opportunity to Lead the Zynex Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 19, 2025 [2][4]. Group 1: Allegations Against Zynex - The complaint alleges that Zynex and its executives made false or misleading statements and failed to disclose critical information, including shipping excess products, inflating revenue, and facing scrutiny from insurers like Tricare [4]. - A report published by medical journal STAT accused Zynex of an "oversupplying scheme," leading to insurers removing the company from their networks [5]. - Following the report, Zynex's stock price dropped by $0.50 per share, or 5$9.35 on June 4, 2024, amid heavy trading volume [5]. Group 2: Financial Performance and Market Reaction - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers and a temporary suspension of payments from Tricare [6]. - The announcement led to a drastic decline in Zynex's stock price, which fell by $3.59 per share, or 51.3$3.41 on March 12, 2025, also on unusually heavy trading volume [7].